We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Six-minute walk distance improved over 52 weeks with ...

Please provide your email address to receive an email when new articles are posted on . United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of ...

Inhaled treprostinil (iTRE) reduces hospitalizations in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD). The study used a real-world database, comparing iTRE initiators ...

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Further, open label extension data published in 2023 showed ...

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million ...

Well, great. Thank you, everybody, for being seated. Welcome. I'm Roger Jeffs, CEO of Liquidia, and welcome to our first ever R&D Day. We're really excited about what we're able to share with you ...

The presence of cardiovascular comorbidities has minimal effect on the efficacy of inhaled or oral treprostinil when used alongside oral monotherapy in patients with pulmonary arterial hypertension ...

The tentative approval cannot take effect because a competing product was granted market exclusivity. A new formulation of treprostinil (Yutrepia) could soon be available to patients with pulmonary ...

No new clinical data is required to add PH-ILD indication as per FDA correspondence Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso Preparing for ...

—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in ...

Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression “Completing enrollment in this trial brings us one step ...